Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $77.63 USD
Change Today +0.70 / 0.91%
Volume 2.5M
DVA On Other Exchanges
Symbol
Exchange
New York
As of 6:40 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

davita healthcare partners i (DVA) Snapshot

Open
$76.69
Previous Close
$76.93
Day High
$77.75
Day Low
$76.39
52 Week High
10/31/14 - $78.52
52 Week Low
05/5/14 - $66.60
Market Cap
16.8B
Average Volume 10 Days
1.7M
EPS TTM
$3.69
Shares Outstanding
215.8M
EX-Date
--
P/E TM
21.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for DAVITA HEALTHCARE PARTNERS I (DVA)

davita healthcare partners i (DVA) Related Businessweek News

View More BusinessWeek News

davita healthcare partners i (DVA) Details

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers, as well as patient and physician focused integrated health care delivery and management services. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2014, the company provided dialysis and administrative services in the United States through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia serving approximately 173,000 patients; operated or provided administrative services to a total of 91 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 7,200 patients; and integrated care management services for approximately 837,300 members under its care in southern California, central and south Florida, southern Nevada, central New Mexico, and central Arizona. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services in the United States. The company was formerly known as DaVita Inc. and changed its name to DaVita HealthCare Partners Inc. in November 2012. DaVita HealthCare Partners Inc. was founded in 1994 and is headquartered in Denver, Colorado.

57,900 Employees
Last Reported Date: 02/26/15
Founded in 1994

davita healthcare partners i (DVA) Top Compensated Officers

Co-Chairman, Chief Executive Officer and Chie...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $213.6K
Chief Executive Officer of Davita Kidney Care...
Total Annual Compensation: $800.0K
Chief Executive Officer of Kidney Care Divisi...
Total Annual Compensation: $765.4K
Chief Accounting Officer
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

davita healthcare partners i (DVA) Key Developments

DaVita HealthCare Partners Inc. and New York Achievement First Announces Ongoing Partnership to Grow Achievement First Organizational Culture

DaVita HealthCare Partners Inc. and New York Achievement First announced an ongoing partnership to help Achievement First grow its organizational culture. The first-of-its-kind program for New York kicked off in May 2014 when Dacia M. Toll, co-CEO and president for Achievement First, and Kent Thiry, co-chairman and CEO of DaVita Healthcare Partners, came together to create an intentional culture that would help enhance the relationship between teachers and parents within the school district. DaVita HealthCare Partners helped create a two-day program that increased stakeholder engagement, better connected parents to the school culture, and established commitments that participants could bring to life at home and at school. DaVita HealthCare Partners continues to support Achievement First with strategic advice as they determine how best to scale the program for future offerings.

DaVita Healthcare Partners Inc.'s DaVita Kidney Care Appoints Mahesh Krishnan as International Chief Medical Officer and Group Vice President of Research and Development

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. announced that Mahesh Krishnan, M.D., MPH, MBA, FASN, will serve as the company's international chief medical officer (CMO) and group vice president of research and development to implement global clinical initiatives. Krishnan previously served as DaVita Kidney Care's vice president of clinical research, innovation and public policy. Prior to joining DaVita Kidney Care in 2009, Krishnan worked in various nephrology leadership positions with Amgen, heading up global health economics and outcomes research for nephrology. He also was responsible for overseeing the Dialysis Outcomes Practice Pattern Study.

DaVita Healthcare Partners Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

DaVita HealthCare Partners Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total net revenue of $3,328,017,000 against $3,063,209,000 a year ago. Operating income was $452,085,000 against $484,179,000 a year ago. Income from continuing operations before income taxes was $354,365,000 against $380,020,000 a year ago. Income from continuing operations was $250,388,000 or $0.96 diluted per share against $244,273,000 or $0.99 diluted per share a year ago. Net income attributable to the company was $208,020,000 or $0.96 diluted per share against $212,278,000 or $0.99 diluted per share a year ago. Free cash flow was $197 million. Adjusted income from continuing operations attributable to the company, excluding the amortization of intangible assets associated with acquisitions, net of tax impacts, was $236 million or $1.09 per share. For the year, the company reported total net revenue of $12,795,106,000 against $11,764,050,000 a year ago. Operating income was $1,815,141,000 against $1,550,134,000 a year ago. Income from continuing operations before income taxes was $1,309,673,000 against $1,124,978,000 a year ago. Income from continuing operations was $863,330,000 or $3.33 diluted per share against $743,965,000 or $2.89 diluted per share a year ago. Net income attributable to the company was $723,114,000 or $3.33 diluted per share against $633,446,000 or $2.95 diluted per share a year ago. Net cash provided by operating activities $1,459,407,000 against $1,773,341,000 a year ago. Additions of property and equipment, net were $641,330,000 against $617,597,000 a year ago. Purchase of intangible assets was $1,018,000 against $2,391,000 a year ago. Adjusted income from continuing operations attributable to the company, excluding a loss contingency reserve and debt refinancing charges was $792 million or $3.64 per share. Adjusted income from continuing operations attributable to the company, excluding a loss contingency reserve and a contingent earn-out obligation adjustment, was $818 million or $3.81 per share. Free cash flow was $1.045 billion. Adjusted operating income excluding a loss contingency reserve was $1.832 billion. Adjusted operating income for the year ended December 31, 2013, excluding a loss contingency reserve, an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions and a contingent earn-out obligation adjustment, was $1.898 billion. Adjusted income from continuing operations attributable to the company for the year, excluding the amortization of intangible assets associated with acquisitions, net of tax impacts, was $896 million and adjusted diluted income from continuing operations per share was $4.13. In addition, adjusted income from continuing operations and adjusted diluted income from continuing operations per share for the year ended December 31, 2014 excluded a loss contingency reserve and debt refinancing charges. Consolidated net debt as on December 31, 2014 was $7,425,825,000. The company currently expects 2015 effective tax rate attributable to be approximately 39.5% to 40.5%. The company still expects consolidated operating income for 2015 to be in the range of $1.750 billion to $1.900 billion. The company expects operating income for Kidney Care for 2015 to be in the range of $1.525 billion to $1.625 billion. The company expects operating income for HCP for 2015 to be in the range of $225 million to $275 million and expects consolidated operating cash flow for 2015 to be in the range of $1.500 billion to $1.700 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVA:US $77.63 USD +0.70

DVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apollo Medical Holdings Inc $0.51 USD +0.1074
Fresenius Medical Care AG & Co KGaA €74.51 EUR +0.119
Fresenius SE & Co KGaA €51.70 EUR -0.011
IPC Healthcare Inc $42.31 USD -0.81
Team Health Holdings Inc $57.11 USD -1.15
View Industry Companies
 

Industry Analysis

DVA

Industry Average

Valuation DVA Industry Range
Price/Earnings 23.1x
Price/Sales 1.3x
Price/Book 3.2x
Price/Cash Flow 12.6x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAVITA HEALTHCARE PARTNERS I, please visit www.davita.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.